Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869216 | 1.00 | CTSK (0.45) | CTSKCTSSTACR1CTSLPPARG | |
| SCHEMBL5869225 | 1.00 | CTSK (0.45) | CTSKCTSSTACR1CTSLPPARG | |
| SCHEMBL7419082 | 1.00 | CTSK (0.45) | CTSKCTSSTACR1CTSLPPARG | |
| SCHEMBL5869445 | 0.85 | GPR34 (0.47) | CTSKTACR1CTSLPPARGPPARA | |
| SCHEMBL5869436 | 0.85 | GPR34 (0.47) | CTSKTACR1CTSLPPARGPPARA | |
| SCHEMBL5869439 | 0.85 | GPR34 (0.47) | CTSKTACR1CTSLPPARGPPARA | |
| SCHEMBL6834071 | 0.84 | CTSK (0.41) | CTSKCTSSCTSLPOLBHSD17B10 | |
| SCHEMBL8248987 | 0.84 | ANPEP (0.52) | CTSKCTSSCTSLPPARGCAPN1 | |
| SCHEMBL5870079 | 0.84 | CTSK (0.48) | CTSKTACR1CTSLPOLBHSD17B10 | |
| SCHEMBL5870077 | 0.84 | CTSK (0.48) | CTSKTACR1CTSLPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CTSK 541/4885CTSS 751/4885TACR1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.